» Articles » PMID: 27529619

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data

Overview
Journal PLoS One
Date 2016 Aug 17
PMID 27529619
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

High resolution melting (HRM) is a simple and rapid method for screening mutations. It offers various advantages for clinical diagnostic applications. Conventional HRM analysis often yields equivocal results, especially for surgically obtained tissues. We attempted to improve HRM analyses for more effective applications to clinical diagnostics. HRM analyses were performed for IDH1R132 and IDH2R172 mutations in 192 clinical glioma samples in duplicate and these results were compared with sequencing results. BRAFV600E mutations were analyzed in 52 additional brain tumor samples. The melting profiles were used for differential calculus analyses. Negative second derivative plots revealed additional peaks derived from heteroduplexes in PCR products that contained mutations; this enabled unequivocal visual discrimination of the mutations. We further developed a numerical expression, the HRM-mutation index (MI), to quantify the heteroduplex-derived peak of the mutational curves. Using this expression, all IDH1 mutation statuses matched those ascertained by sequencing, with the exception of three samples. These discordant results were all derived from the misinterpretation of sequencing data. The effectiveness of our approach was further validated by analyses of IDH2R172 and BRAFV600E mutations. The present analytical method enabled an unequivocal and objective HRM analysis and is suitable for reliable mutation scanning in surgically obtained glioma tissues. This approach could facilitate molecular diagnostics in clinical environments.

Citing Articles

The cortical high-flow sign in oligodendroglioma, IDH-mutant and 1p/19q-codeleted is correlated with histological cortical vascular density.

Yamashita K, Murayama R, Itoyama M, Kikuchi K, Kusunoki M, Kuga D Neuroradiology. 2025; 67(2):291-298.

PMID: 39831960 DOI: 10.1007/s00234-024-03538-1.


Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma.

Otsuji R, Hata N, Yamamoto H, Kuga D, Hatae R, Sangatsuda Y Neurooncol Adv. 2024; 6(1):vdae069.

PMID: 39022644 PMC: 11252564. DOI: 10.1093/noajnl/vdae069.


Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects.

Penkova A, Kuziakova O, Gulaia V, Tiasto V, Goncharov N, Lanskikh D Front Mol Biosci. 2023; 10:1216102.

PMID: 37908227 PMC: 10613994. DOI: 10.3389/fmolb.2023.1216102.


Cortical high-flow sign on arterial spin labeling: a novel biomarker for IDH-mutation and 1p/19q-codeletion status in diffuse gliomas without intense contrast enhancement.

Yamashita K, Togao O, Kikuchi K, Kuga D, Sangatsuda Y, Fujioka Y Neuroradiology. 2023; 65(9):1415-1418.

PMID: 37367991 DOI: 10.1007/s00234-023-03186-x.


Predicting TERT promoter mutation status using H-MR spectroscopy and stretched-exponential model of diffusion-weighted imaging in IDH-wildtype diffuse astrocytic glioma without intense enhancement.

Yamashita K, Hatae R, Kikuchi K, Kuga D, Hata N, Yamamoto H Neuroradiology. 2023; 65(8):1205-1213.

PMID: 37308686 DOI: 10.1007/s00234-023-03177-y.


References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Chi A, Batchelor T, Yang D, Dias-Santagata D, Borger D, Ellisen L . BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013; 31(14):e233-6. DOI: 10.1200/JCO.2012.46.0220. View

3.
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

4.
Kanamori M, Kikuchi A, Watanabe M, Shibahara I, Saito R, Yamashita Y . Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. J Neurosurg. 2014; 120(6):1288-97. DOI: 10.3171/2014.3.JNS131505. View

5.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. PMC: 3229304. DOI: 10.1016/j.ccr.2010.12.014. View